ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Mental Health
New Antidepressant Improved Sexual Function in Depressed Men and Women
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="BadassBlues" data-source="post: 243312" data-attributes="member: 38526"><p>It appears they have changed the name. There were some press releases regarding having a 3rd party doing the marketing as well:</p><p></p><p>[URL unfurl="true"]https://fabrekramer.com/nda-amendment-for-exxua/[/URL]</p><p></p><h4>Fabre-Kramer Submits NDA Amendment for <strong><em><u>EXXUA™</u></em></strong> for Treatment of Major Depressive Disorder</h4><p>HOUSTON, Jan. 04, 2023 (<u><a href="https://www.prnewswire.com/news-releases/fabre-kramer-submits-nda-amendment-for-exxua-for-treatment-of-major-depressive-disorder-301712935.html?tc=eml_cleartime" target="_blank">View press release on CisionNewswire.com)</a></u></p><p></p><p>New Class of Antidepressant’s Novel Mechanism Uniquely and Directly Addresses Important Unmet Needs</p><p></p><p>HOUSTON, Jan. 4, 2023 /PRNewswire/ — Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug Administration (FDA) for its novel mechanism antidepressant EXXUA™ <strong><u><em>(gepirone ER) </em></u></strong>for treatment of Major Depressive Disorder (MDD).</p></blockquote><p></p>
[QUOTE="BadassBlues, post: 243312, member: 38526"] It appears they have changed the name. There were some press releases regarding having a 3rd party doing the marketing as well: [URL unfurl="true"]https://fabrekramer.com/nda-amendment-for-exxua/[/URL] [HEADING=3]Fabre-Kramer Submits NDA Amendment for [B][I][U]EXXUA™[/U][/I][/B] for Treatment of Major Depressive Disorder[/HEADING] HOUSTON, Jan. 04, 2023 ([U][URL='https://www.prnewswire.com/news-releases/fabre-kramer-submits-nda-amendment-for-exxua-for-treatment-of-major-depressive-disorder-301712935.html?tc=eml_cleartime']View press release on CisionNewswire.com)[/URL][/U] New Class of Antidepressant’s Novel Mechanism Uniquely and Directly Addresses Important Unmet Needs HOUSTON, Jan. 4, 2023 /PRNewswire/ — Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug Administration (FDA) for its novel mechanism antidepressant EXXUA™ [B][U][I](gepirone ER) [/I][/U][/B]for treatment of Major Depressive Disorder (MDD). [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Mental Health
New Antidepressant Improved Sexual Function in Depressed Men and Women
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top